Anti-viral azide containing compounds
US10632133B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 7, 2017 |
| Grant date | Apr 28, 2020 |
| Priority date | — |
| Expiry date | Dec 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.